American International Group Inc. Sells 2,999 Shares of Haemonetics Co. (NYSE:HAE)

American International Group Inc. trimmed its holdings in Haemonetics Co. (NYSE:HAEFree Report) by 3.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 93,060 shares of the medical instruments supplier’s stock after selling 2,999 shares during the quarter. American International Group Inc. owned about 0.18% of Haemonetics worth $7,958,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. increased its stake in Haemonetics by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 5,380,858 shares of the medical instruments supplier’s stock valued at $482,017,000 after purchasing an additional 27,146 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Haemonetics by 7.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 826,731 shares of the medical instruments supplier’s stock valued at $70,697,000 after purchasing an additional 59,670 shares in the last quarter. Westfield Capital Management Co. LP increased its stake in Haemonetics by 27.2% during the 4th quarter. Westfield Capital Management Co. LP now owns 712,061 shares of the medical instruments supplier’s stock valued at $60,888,000 after purchasing an additional 152,098 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in Haemonetics by 1.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 534,694 shares of the medical instruments supplier’s stock valued at $45,722,000 after purchasing an additional 8,901 shares in the last quarter. Finally, Norges Bank bought a new stake in Haemonetics during the 4th quarter valued at about $28,591,000. 99.67% of the stock is currently owned by institutional investors.

Haemonetics Stock Performance

Shares of HAE stock opened at $85.61 on Monday. The company has a 50 day moving average price of $88.91 and a 200-day moving average price of $83.49. Haemonetics Co. has a 52 week low of $70.74 and a 52 week high of $97.97. The firm has a market capitalization of $4.35 billion, a PE ratio of 37.38, a P/E/G ratio of 1.57 and a beta of 0.37. The company has a quick ratio of 1.50, a current ratio of 2.56 and a debt-to-equity ratio of 0.83.

Haemonetics (NYSE:HAEGet Free Report) last posted its quarterly earnings data on Thursday, May 9th. The medical instruments supplier reported $0.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.02. The company had revenue of $343.00 million for the quarter, compared to the consensus estimate of $329.53 million. Haemonetics had a net margin of 8.98% and a return on equity of 22.25%. The firm’s revenue was up 12.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.77 earnings per share. As a group, equities research analysts expect that Haemonetics Co. will post 4.55 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Stewart W. Strong sold 733 shares of the firm’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $96.04, for a total value of $70,397.32. Following the transaction, the insider now owns 15,608 shares of the company’s stock, valued at $1,498,992.32. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, insider Stewart W. Strong sold 733 shares of the firm’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $96.04, for a total value of $70,397.32. Following the transaction, the insider now owns 15,608 shares of the company’s stock, valued at $1,498,992.32. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Stewart W. Strong sold 686 shares of Haemonetics stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $95.11, for a total transaction of $65,245.46. Following the transaction, the insider now directly owns 18,196 shares in the company, valued at approximately $1,730,621.56. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 27,380 shares of company stock valued at $2,445,816. 1.79% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. StockNews.com lowered shares of Haemonetics from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Needham & Company LLC restated a “hold” rating on shares of Haemonetics in a research note on Friday, May 10th. Barrington Research raised their price objective on shares of Haemonetics from $105.00 to $107.00 and gave the company an “outperform” rating in a research note on Friday, May 10th. JMP Securities lifted their price target on shares of Haemonetics from $115.00 to $125.00 and gave the stock a “market outperform” rating in a research note on Friday, May 10th. Finally, TheStreet lowered shares of Haemonetics from a “b-” rating to a “c+” rating in a research note on Thursday, February 29th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, Haemonetics has an average rating of “Hold” and an average price target of $108.67.

Read Our Latest Analysis on HAE

Haemonetics Profile

(Free Report)

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.

Featured Articles

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.